Analysts Jefferies upgraded Chemed (CHE) to Buy and raised target price to $620, expecting 22% upside
Jefferies has upgraded Chemed to a 'buy' rating and increased its price target to $620, indicating a potential 22% upside, following the company's strong third-quarter earnings that exceeded expectations. This upgrade reflects confidence in Chemed's recovery from recent operational challenges and its ability to regain a premium valuation.